Ranajit Nath

Mr. Ranajit Nath

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
Ashok AspatwarAshok Aspatwar
Ashok Aspatwar
RNRanajit Nath
Ranajit Nath
RBRatul Bhowmik
Ratul Bhowmik
RJRajesh Jesudasan
Rajesh Jesudasan
This content was retracted at the authors' request to allow for corrections to the preprint. The study of artificial intelligence (AI), a multidimensional field, empowers machines with the ability to understand, reason, learn, and perform tasks autonomously. As a pivotal branch of computer science, AI excels in analyzing complex medical data and uncovering significant relationships for diverse diagnostic purposes. In neurology, innovative AI techniques have revolutionized diagnostics, management, and outcome prediction, opening new avenues for tackling neurological disorders. AI encompasses two key subsets: machine learning (ML) and deep learning (DL), which have gained immense popularity for predicting bioactivity, toxicology, physical and chemical properties, formulation quality, and drug-target interactions. The complexity of neurological diseases (ND) presents unique challenges in developing treatments for the central nervous system (CNS), given obstacles like the blood-brain barrier and high medication attrition rates. However, AI algorithms, leveraging vast datasets, efficiently analyze, interpret, and predict unknown facts, significantly accelerating CNS drug discovery. Deep learning architectures have furthered our understanding of AI's potential to address complex CNS disease issues, transforming the drug development landscape. This review delves into AI, ML, and their applications in advancing CNS drug and formulation development. It provides comprehensive, up-to-date insights on AI/ML advancements in neurology, emphasizing nanoparticle-based drug delivery systems. Additionally, the review covers ML algorithms' roles in de novo drug design, structure-based drug design, ligand-based drug design, absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction, and drug repurposing. Despite notable progress, significant challenges remain in enhancing AI's practical application in neurology. Overcoming these hurdles requires compiling extensive data and developing interpretable AI systems, paving the way for groundbreaking advancements in CNS drug development.

15 July 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
Ashok AspatwarAshok Aspatwar
Ashok Aspatwar
RNRanajit Nath
Ranajit Nath
RBRatul Bhowmik
Ratul Bhowmik
RJRajesh Jesudasan
Rajesh Jesudasan
This content was retracted at the authors' request to allow for corrections to the preprint. Nanotechnology has had a profound influence on human existence. Overcoming the many difficulties presented by various disorders, particularly neurological disorders (NDs), is a crucial approach. Various types of nanomaterials, including lipid nanoparticles, nanoliposomes, nano-micelles, polymer nanoparticles, and metal nanoparticles, along with different methods of transportation arrangements such as poly lactic o-glycolic acid, lactoferrin, and poly butyl cyanoacrylate, have the potential to greatly enhance the effectiveness, reduce the risk of negative outcomes, improve stability, and enhance the pharmacokinetics of many medications. Neurological disorders (NDs) are a subset of debilitating diseases that have a significant impact on a large population worldwide. Prior studies have shown that various formulations including nanotechnology, derived from a range of natural substances such as curcumin, quercetin, Ginkgo Biloba, and nigella sativa, significantly improve the well-being of persons with neurological disorders. The blood-brain barrier (BBB) is the primary obstacle preventing the passage of medications into the central nervous system (CNS), posing a challenge in the treatment of neurological disorders (NDs). . Engineered nanoparticles with altered physicochemical characteristics, ranging in size from 1 to 100 nm, can be utilized to enhance the effectiveness, cellular uptake, selective delivery, and distribution of specific particles to the brain. Nanoparticles derived from therapeutic plants and their constituents, known as phytomedicine from nano, have gained recognition for their abundant supply, ability to precisely target the brain, and reduced risk of adverse effects. These nanoparticles are increasingly important in the development of advanced neuro-therapeutics. This paper discusses the potential and ongoing advancements in using the combination of phytomedicine and nanotechnology for the treatment of neurological disorders. To summarize, herbal-based nanosystems, either alone or in combination with other drugs, demonstrate potential efficacy in the treatment of neurological disorders..

5 July 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
Ashok AspatwarAshok Aspatwar
Ashok Aspatwar
RBRatul Bhowmik
Ratul Bhowmik
RNRanajit Nath
Ranajit Nath
BSBhabani Sankar Satapathy
Bhabani Sankar Satapathy
PSPuja Saha
Puja Saha
SPSeppo Parkkila
Seppo Parkkila
This content was retracted at the authors' request to allow for corrections to the preprint. Pharmacokinetic-pharmacodynamics (PK/PD) modeling has been recognized as an essential tool for the planning and execution of clinical pharmacology investigations throughout the formulation development process. The utilization of PK/PD modeling to optimize dosage recommendations and therapeutic medication monitoring is on the rise, and PK/PD model-based dose individualization is going to play a crucial role in personalized medicine. In recent years, higher costs and low productivity in drug development have got a lot of attention. Fewer than 10% of innovative medications that survive clinical trials are commercialized, while many more fail in preclinical research. Based on preclinical and clinical data, the FDA now defines model-based drug development as a key tool in the assessment of therapeutic efficacy and safety of medications. As successful drug delivery to central nervous system (CNS) diseases has been a tough challenge, effective use of PK/PD models can permit merging data from clinical trials with quantified exposure and provide highly convincing explanations for disparities in the results of distinct investigations. To improve CNS therapies and drug development, details of inter-species and inter-condition variations are needed to enable target site pharmacokinetics and associated CNS effects between disease states. The present review covers the potential of PK/PD modeling in the current scenario of drug development with a special emphasis on CNS-based targeted delivery. Additionally, challenges associated with the field have also been addressed.